Axcella Health, a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced the issuance of U.S. Patent 10,201,513 with claims covering compositions of matter including the company’s AXATM Candidate AXA1125, independent of any particular use.
February 12, 2019
· 3 min read